Patient HLA class I genotypes and detected CAIX-CAR immunoreactive epitopes
| Cohort/patient . | HLA class I genotypes . | Detected CAIX-CAR immune reactive epitopes . | |
|---|---|---|---|
| aa numbers . | FR/CDR region . | ||
| 1/2 | A*02,—; B*61, 62; Cw2, 3 | ne | — |
| 1/3 | A*01, 24; B*08, 51; Cw4,— | ne | — |
| 2/4 | A*02 [0201/0203], —; B*15 [1501/1510], — | 65-83 | VH-CDR2 |
| 2/5 | A*01, 24[2402]; B*51[5101], 57 | 117-131 | VH-CDR3 |
| 2/6 | A*03, 32; B*27,35 | 257-271 | VL-FR4 |
| 2/7 | A*02,11; B*35, 51 | 257-271 | VL-FR4 |
| 3/9 | A*02, 24; B*13, 15 [1521] | 57-75 | VH-CDR2 |
| 3/10 | A*02, —; B*08, 35 | —† | — |
| 3/11 | A*03, 29; B*07, — | ne | — |
| Cohort/patient . | HLA class I genotypes . | Detected CAIX-CAR immune reactive epitopes . | |
|---|---|---|---|
| aa numbers . | FR/CDR region . | ||
| 1/2 | A*02,—; B*61, 62; Cw2, 3 | ne | — |
| 1/3 | A*01, 24; B*08, 51; Cw4,— | ne | — |
| 2/4 | A*02 [0201/0203], —; B*15 [1501/1510], — | 65-83 | VH-CDR2 |
| 2/5 | A*01, 24[2402]; B*51[5101], 57 | 117-131 | VH-CDR3 |
| 2/6 | A*03, 32; B*27,35 | 257-271 | VL-FR4 |
| 2/7 | A*02,11; B*35, 51 | 257-271 | VL-FR4 |
| 3/9 | A*02, 24; B*13, 15 [1521] | 57-75 | VH-CDR2 |
| 3/10 | A*02, —; B*08, 35 | —† | — |
| 3/11 | A*03, 29; B*07, — | ne | — |
ne indicates not evaluated due to limited immune reactivity or technical restrictions.
No immunoreactive epitope detected.